Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$4.78 - $7.96 $10.1 Million - $16.8 Million
-2,112,918 Closed
0 $0
Q1 2021

May 18, 2021

BUY
$5.49 - $9.36 $11.6 Million - $19.8 Million
2,112,918 New
2,112,918 $12.1 Million
Q3 2020

Nov 16, 2020

SELL
$11.64 - $16.3 $698,400 - $978,000
-60,000 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$5.38 - $16.14 $322,800 - $968,400
60,000 New
60,000 $962,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $395M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Opaleye Management Inc. Portfolio

Follow Opaleye Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Opaleye Management Inc. with notifications on news.